GLP-1 medications, such as Ozempic, may interact with other drugs, causing very low blood sugar levels or disrupting the ...

In addition, in the coming years, oral GLP-1 receptor agonists and injectable formulations that require less-frequent ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Most patients do not need to pause their GLP-1 medications prior to elective surgery, according to updated guidance from several medical societies, including the American Society of Anesthesiologists, ...

Pfizer executives are still bullish on the opportunity for its own obesity and diabetes drugs under development, eyeing a potential opening for oral versions and an improved safet ...

For instance, new formulations and delivery methods, such as oral GLP-1RAs, are being developed to ... Cost remains a ...

an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeu ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...